$20.52 $0.26 (1.3%)

04:00 PM EST on 11/21/19

Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Current Price $20.52 Mkt Cap $7.3B
Open $20.08 P/E Ratio 0.00
Prev. Close $20.26 Div. (Yield) $0.00 (0.0%)
Daily Range $19.61 - $21.10 Volume 8,184,243
52-Wk Range $12.44 - $24.67 Avg. Daily Vol. 9,735,378

Caps

How do you think NASDAQ:AMRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

360 Outperform
30 Underperform
 

All-Star Players

47 Outperform
11 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top NASDAQ:AMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

meridius91 (81.66)
Submitted September 27, 2018

After the recent approval of Vascepa, this stock is poised for greatness. With it's massive benefit to patients ON TOP of industry standard statins and relatively cheap price in comparison to alternatives on the market, Amarin could be at the front… More

chris293 (62.34)
Submitted May 07, 2013

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

NASDAQ:AMRN VS S&P 500 (SPY)

Fools bullish on NASDAQ:AMRN are also bullish on:

Fools bearish on NASDAQ:AMRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AMRN.

Recs

0
Member Avatar emtking (62.84) Submitted: 11/9/2019 3:06:20 PM : Outperform Start Price: $16.97 NASDAQ:AMRN Score: +20.14

FDA PDUFA date of November 14th, 2019. Essentially, FDA evaluation if concentrated fish oils based pills can reduce incidence of heart disease. In real life, at one point about 7-8 years ago, I owned shares of AMRN when it was under $1/sh. Sold. Lost faith. So sad :(

Recs

0
Member Avatar TL22 (< 20) Submitted: 10/24/2019 3:02:44 AM : Outperform Start Price: $16.34 NASDAQ:AMRN Score: +22.48

The excellent results of the REDUCE-IT study cannot be overlooked. Sales of Vascepa continue to increase as more Doctors become aware of its benefits. FDA - based on the the REDUCE-IT results, a study which the FDA approved the criteria for - will (little to no doubt) allow an expanded label for Vascepa use towards the end of this year. This will result in an immediate increase in share price, which will continue to increase along with the sale of Vascepa.

Recs

0
Member Avatar Jordrok (85.37) Submitted: 8/5/2019 1:18:43 PM : Outperform Start Price: $16.53 NASDAQ:AMRN Score: +15.37

Crazy growth.

Leaderboard

Find the members with the highest scoring picks in AMRN.

Score Leader

AWWWWW

AWWWWW (52.31) Score: +2,017.51

The Score Leader is the player with the highest score across all their picks in AMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
AWWWWW 52.31 12/31/2014 Outperform 1Y $0.95 +2,066.61% +49.11% +2,017.51 0 Comment
Playa14 < 20 12/26/2014 Outperform 5Y $0.99 +1,972.73% +48.98% +1,923.75 0 Comment
efarev 98.18 2/3/2015 Outperform 5Y $1.03 +1,892.23% +52.18% +1,840.06 0 Comment
BENIVZ14 < 20 12/15/2014 Outperform 5Y $1.09 +1,782.57% +53.65% +1,728.92 0 Comment
rantomac 70.65 2/10/2015 10/31/2017 Outperform 5Y $1.12 +1,732.14% +50.74% +1,681.40 0 Comment
GoPack 41.56 11/21/2014 Outperform 5Y $1.28 +1,503.12% +49.46% +1,453.66 0 Comment
jamesjass < 20 9/17/2014 Outperform 1Y $1.33 +1,442.86% +54.57% +1,388.28 0 Comment
pro64grammer 29.22 9/12/2014 Outperform 5Y $1.40 +1,370.97% +55.31% +1,315.66 0 Comment
velo15 < 20 3/31/2016 Outperform 5Y $1.51 +1,258.94% +50.72% +1,208.22 0 Comment
surfco3 88.21 4/6/2016 Outperform 5Y $1.59 +1,190.57% +51.91% +1,138.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AMRN.